1,413 results match your criteria Acta neurologica Scandinavica. Supplementum[Journal]


Sleep quality and arousal in migraine and tension-type headache: the headache-sleep study.

Acta Neurol Scand Suppl 2014 (198):47-54

Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway; Department of Neurology and Clinical Neurophysiology, St. Olavs Hospital, Trondheim, Norway.

Objectives: The present paper summarizes and compares data from our studies on subjective and objective sleep quality and pain thresholds in tension-type headache (TTH), migraine, and controls.

Material And Methods: In a blinded controlled explorative study, we recorded polysomnography (PSG) and pressure, heat, and cold pain thresholds in 34 controls, 20 TTH, and 53 migraine patients. Sleep quality was assessed by questionnaires, sleep diaries, and PSG. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12237DOI Listing
December 2014
1 Read

Diffusion-weighted lesions in acute ischaemic stroke patients with migraine.

Acta Neurol Scand Suppl 2014 (198):41-6

Department of Neurology, Haukeland University Hospital, Bergen, Norway; Institute of Clinical Medicine, University of Bergen, Bergen, Norway.

Objectives: There is increasing knowledge about an association between migraine and ischaemic stroke. Cortical spreading depression (CSD) is the probable biological substrate of migrainous aura. To investigate the influence of CSD on the apparent stroke - migraine association, we hypothesized that magnetic resonance (MR) diffusion weighted images of acute ischaemic stroke patients would reveal an association between small cortical infarctions and migraine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12236DOI Listing
December 2014

Mild stroke: safety and outcome in patients receiving thrombolysis.

Acta Neurol Scand Suppl 2014 (198):37-40

Department of Clinical Medicine, University of Bergen, Bergen, Norway.

Objectives: The aim of this study was to compare the short-term clinical outcome of patients with acute cerebral ischemia and mild symptoms receiving rt-PA with that of patients with acute cerebral ischemia and mild symptoms not treated with rt-PA, and to investigate the frequency of symptomatic intracranial hemorrhage (sICH) in these patients.

Materials And Methods: All patients with confirmed ischemic stroke/TIA and mild symptoms were included. Mild symptoms were defined as NIHSS score≤5 on admission. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12235DOI Listing
December 2014

MRI evaluation of grey matter atrophy and disease course in multiple sclerosis: an overview of current knowledge.

Acta Neurol Scand Suppl 2014 (198):32-6

Department of Neurology, Stavanger University Hospital, Stavanger, Norway; The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway.

Multiple sclerosis (MS) is characterized by chronic inflammation of the central nervous system, and magnetic resonance imaging (MRI) is used as both a diagnostic tool and a parameter in the clinical evaluation. Multiple sclerosis was long regarded as a disease of the white matter (WM) in the brain, which can be visualized by the standard MRI used in daily practice. There is an increasing amount of evidence that grey matter (GM) pathology plays a role from the start of the MS disease and throughout the clinical course. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12234DOI Listing
December 2014

Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries.

Acta Neurol Scand Suppl 2014 (198):26-31

Department of Clinical Medicine, University of Bergen, Bergen, Norway.

Objectives: There is a wide variation in reported prevalence and incidence of myasthenia gravis (MG). In this study, we aimed to evaluate the validity of two nationwide databases by comparing prevalence and incidence rates reported from three recent studies using the two databases as case-finding method.

Materials And Methods: Two different Norwegian nationwide databases were used: the acetylcholine receptor antibody database (reference cohort) and the Norwegian Prescription Database (NorPD) (study cohort). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12233DOI Listing
December 2014

Advances in genetic diagnosis of neurological disorders.

Authors:
M Toft

Acta Neurol Scand Suppl 2014 (198):20-5

Department of Neurology, Oslo University Hospital - Rikshospitalet, Oslo, Norway.

Neurogenetics has developed enormously in recent years, and the genetic basis of human disorders is being unravelled rapidly. Many neurological disorders are Mendelian disorders, caused by mutations in genes involved in normal function of the brain, spinal cord, peripheral nerves or muscles. Due to high costs and time-consuming procedures, genetic tests have normally been performed late in the diagnostic process, when clinical examination and other tests have indicated a specific gene as the likely disease cause. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12232DOI Listing
December 2014

Dystonia--new advances in classification, genetics, pathophysiology and treatment.

Authors:
I M Skogseid

Acta Neurol Scand Suppl 2014 (198):13-9

Department of Neurology, Oslo University Hospital, Oslo, Norway.

Dystonia is a heterogeneous movement disorder and has been defined as 'a syndrome of sustained muscle contractions, frequently causing twisted and repetitive movements, or abnormal postures'. The classification of dystonia has developed along with increasing knowledge, and different schemes have been suggested, including age at onset, body distribution, and etiology as the main differentiating factors. A revised definition and a new classification of dystonia have now been proposed by a group of leading dystonia experts and will be referred here. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12231DOI Listing
December 2014
1 Read

Clinical and genetic studies in a family with a novel mutation in the sepiapterin reductase gene.

Acta Neurol Scand Suppl 2014 (198):7-12

Department of Neurology, Drammen Hospital, Vestre Viken Health Trust, Drammen, Norway.

Objectives: Sepiapterin reductase deficiency is a rare, but treatable inherited disorder of tetrahydrobiopterin and neurotransmitter metabolism. This disorder is most probably underdiagnosed. To date, only 44 cases have been described in the literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12230DOI Listing
December 2014

Neurological disorders in the Global Burden of Disease 2010 study.

Acta Neurol Scand Suppl 2014 (198):1-6

Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway; Norwegian National Headache Centre, St. Olavs University Hospital, Trondheim, Norway.

Background: The Global Burden of Disease study (GBD) is a large international initiative to collect and systematize data on disease burden expressed in non-economic terms, to allow comparisons across different disease conditions and countries.

Objectives: To use data from the large GBD 2010 database to determine the importance of neurological disorders in Norway, and to compare it with global data on the same disorders.

Materials And Methods: Relevant data were extracted from the Lancet publication from December 2012, and from the interactive website of the Institute of Health Metrics and Evaluation on GBD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12229DOI Listing
December 2014
1 Read

Perampanel: expanding therapeutic options for patients with medically refractory secondary generalized convulsive seizures.

Authors:
D Ko R E Ramsay

Acta Neurol Scand Suppl 2013 (197):36-43

Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.

To evaluate the efficacy of adjunctive, once-daily perampanel against secondarily generalized (SG) seizures in three Phase III trials (studies 304, 305, and 306) and their extension (study 307). The Phase III studies enrolled patients (≥ 12 years) with uncontrolled partial-onset seizures despite treatment with 1-3 concomitant antiepileptic drugs. Patients completing the core Phase III studies were eligible for the extension study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12103DOI Listing
September 2013

Safety and tolerability of perampanel: a review of clinical trial data.

Acta Neurol Scand Suppl 2013 (197):30-5

Hospital Universitario Fundación Jiménez Diaz and CIBERER, Madrid, Spain.

The Phase II and Phase III clinical development program of perampanel is providing a wealth of data on the safety and tolerability of this alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist as an adjuvant treatment for refractory partial-onset seizures. In Phase II dose-finding studies, perampanel was associated with an acceptable tolerability profile up to the maximum evaluated dose of 12 mg/day. Subsequent multinational, multicenter, randomized, double-blind, placebo-controlled Phase III registration studies further supported the tolerability of perampanel across the dose range 2-12 mg/day, with interim data from ongoing extension studies indicating that safety outcomes may be maintained over several years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12102DOI Listing
September 2013

Efficacy of perampanel: a review of clinical trial data.

Acta Neurol Scand Suppl 2013 (197):25-9

Department of Neurology, University of Ulm, Ulm, Germany.

The efficacy of adjunctive perampanel has been investigated in an extensive clinical development program across a broad, multinational population of patients with refractory partial-onset seizures. Further to the results of two Phase II dose-finding studies, perampanel was evaluated in three large Phase III registration studies at the predicted no-effect dose of 2 mg/day and the predicted effective doses of 4, 8, and 12 mg/day. In all three studies, perampanel 4, 8, and 12 mg/day consistently provided significant reductions in the frequency of partial-onset seizures compared with placebo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12101DOI Listing
September 2013

Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist.

Acta Neurol Scand Suppl 2013 (197):19-24

Department of Neurology, School of Medicine and Center for Neuroscience, University of California, Davis, Sacramento, CA 95817, USA.

Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile; E2007] is a potent, selective, orally active non-competitive AMPA receptor antagonist developed for the treatment of epilepsy. Perampanel has a 2,3'-bipyridin-6'-one core structure, distinguishing it chemically from other AMPA receptor antagonist classes. Studies in various physiological systems indicate that perampanel selectively inhibits AMPA receptor-mediated synaptic excitation without affecting NMDA receptor responses. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ane.12100
Publisher Site
http://dx.doi.org/10.1111/ane.12100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506647PMC
September 2013
2 Reads

AMPA receptors as a molecular target in epilepsy therapy.

Authors:
M A Rogawski

Acta Neurol Scand Suppl 2013 (197):9-18

Department of Neurology, School of Medicine and Center for Neuroscience, University of California, Davis, Sacramento, CA 95817, USA.

Epileptic seizures occur as a result of episodic abnormal synchronous discharges in cerebral neuronal networks. Although a variety of non-conventional mechanisms may play a role in epileptic synchronization, cascading excitation within networks of synaptically connected excitatory glutamatergic neurons is a classical mechanism. As is the case throughout the central nervous system, fast synaptic excitation within and between brain regions relevant to epilepsy is mediated predominantly by AMPA receptors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12099DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506648PMC
September 2013
1 Read

Development of perampanel in epilepsy.

Acta Neurol Scand Suppl 2013 (197):3-8

Eisai Neuroscience Product Creation Unit, Woodcliff Lake, NJ 07677, USA.

Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors play a key role in mediating glutamatergic transmission in the cortex. Perampanel (2-[2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl] benzonitrile) is a potent, orally active, highly selective, non-competitive AMPA-type glutamate receptor antagonist, identified via a focused discovery program at Eisai Research Laboratories. Development of perampanel as adjunctive therapy for the treatment of partial-onset seizures was planned in keeping with regulatory guidance and guidelines on antiepileptic drug (AED) development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12098DOI Listing
September 2013
2 Reads

Assess, compare and enhance the status of Persons with Multiple Sclerosis (MS) in Europe: a European Register for MS.

Acta Neurol Scand Suppl 2012 (195):24-30

Department of Clinical and Experimental Medicine, University of Sassari, Viale Ssan Pietro 10, Sassari, Italy.

Objectives: Persons with multiple sclerosis (PwMS) experience health-related quality of life (HRQoL) problems greatly differing across Europe, and the European Union (EU) faces deep inequalities in MS management from country to country. Through the establishment of a European MS Register (EUReMS), an effective action is proposed to improve the overall knowledge on MS and support effective intervention programmes at EU and national political level. EUReMS aims to achieve consensus on its mission and vision, to define existing data providers, to develop models driving future MS health policies and research, to develop an information technology (IT) infrastructure for a data set, to develop a European shared governance and to secure providers' data provision into EUReMS. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ane.12024
Publisher Site
http://dx.doi.org/10.1111/ane.12024DOI Listing
September 2013
2 Reads

Cortical pathology in multiple sclerosis: experimental approaches to studies on the mechanisms of demyelination and remyelination.

Acta Neurol Scand Suppl 2012 (195):97-102

Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of unknown etiology that can involve all parts of the central nervous system and is unique to humans. Therefore, analysis of human tissue is critical for generating hypotheses for testing in animal or in vitro models and for validating research findings from these experimental models. This article reviews data on demyelination and remyelination in the cerebral cortex. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12041DOI Listing
September 2013

Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls.

Acta Neurol Scand Suppl 2012 (195):90-6

The KG Jebsen Centre for MS-research, Department of Clinical Medicine, University of Bergen, Bergen, Norway.

Objectives: The aim of the present study was to identify proteins in cerebrospinal fluid (CSF) with different abundance between patients with relapsing-remitting multiple sclerosis (RRMS) and controls. Such proteins may be diagnostic biomarkers and contribute with novel information about the disease pathogenesis.

Materials And Methods: Cerebrospinal fluid from patients with RRMS (n = 17) and controls (n = 17) were trypsin digested and analyzed in a label-free fashion using liquid chromatography mass spectrometry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12029DOI Listing
September 2013
2 Reads

Fcγ receptors in Norwegian multiple sclerosis patients and healthy controls.

Acta Neurol Scand Suppl 2012 (195):84-9

Department of Clinical Medicine, University of Bergen, Bergen, Norway.

Background: Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system in genetically susceptible persons. Fcγ receptors (FcγR) are involved in autoimmune diseases.

Patients And Methods: Sixteen Norwegian patients with relapsing-remitting MS (RRMS) were studied to see whether treatment with either interferon-beta (INF-β) or glatiramer acetate (GA) influenced the proportion of FcγR1a, FcγR2a, and FcγR3b positive monocytes, granulocytes, or lymphocytes or FcγR1a, FcγR2a, and FcγR2b mRNA levels in leukocytes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12026DOI Listing
September 2013

From genes to characteristics of multiple sclerosis.

Authors:
H F Harbo I-L Mero

Acta Neurol Scand Suppl 2012 (195):76-83

Department of Neurology, Oslo University Hospital, Oslo, Norway.

Multiple sclerosis (MS) is an inflammatory, demyelinating heterogeneous disease of the central nervous system, probably caused by an interaction of common genetic and environmental factors. Much progress has been made through the last few years in genetic studies of MS, and a growing list of genetic risk factors is now available. Biobanking and large collaborations have been prerequisites for this research, and detailed genetic and molecular characterizations are underway, with hopes for to translating new knowledge about MS pathogenesis and characteristics of the disease to personalized, better treatment options for each patient with MS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12027DOI Listing
September 2013
1 Read

Polyunsaturated fatty acids in multiple sclerosis therapy.

Acta Neurol Scand Suppl 2012 (195):70-5

Department of Neurology, Norwegian Multiple Sclerosis Competence Centre, Haukeland University Hospital, Bergen, Norway.

Background: Results from epidemiological and uncontrolled intervention studies in multiple sclerosis (MS) suggest a beneficial disease-modifying effect of increased intake of polyunsaturated fatty acids (PUFAs).

Objective: To review the current evidence from animal studies and randomised controlled trials on the therapeutic effect of PUFAs in MS.

Methods: We searched PubMed and Medline for articles using the terms 'polyunsaturated fatty acids', 'eicosapentaenoic acid', 'docosahexaenoic acid', 'linoleic acid', 'linolenic acid', 'omega-3' and 'omega-6' combined with 'multiple sclerosis', 'randomised controlled trials', 'animal models', 'experimental autoimmune encephalomyelitis' and 'cuprizone'. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12034DOI Listing
September 2013
2 Reads

Vitamin D supplementation and monitoring in multiple sclerosis: who, when and wherefore.

Acta Neurol Scand Suppl 2012 (195):63-9

Department of Neurology, Akershus University Hospital, Lørenskog, Norway.

Objectives: Observational studies suggest that increasing the serum concentration of 25-hydroxyvitamin D with 50 nm could halve the relapse risk in relapsing-remitting multiple sclerosis (MS). Assuming that the association between disease activity and vitamin D status is entirely causal may however exaggerate the potential benefit. The aim of this paper is to address whether and how vitamin D should be monitored in patients with MS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12028DOI Listing
September 2013

Month of birth as a risk factor for multiple sclerosis: an update.

Acta Neurol Scand Suppl 2012 (195):58-62

Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Bergen, Norway.

Background: Several studies have indicated month of birth as a risk factor for multiple sclerosis (MS) susceptibility and disease progression.

Methods: We performed a systematic search on PubMed and Medline up to May 2012 using the search string 'multiple sclerosis' and 'month of birth' or 'season of birth'. In addition, congress abstracts and the reference lists of the publications identified were examined for further citations of relevance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12040DOI Listing
September 2013
1 Read

Health-related quality of life and disease-modifying treatment behaviour in relapsing-remitting multiple sclerosis--a multicentre cohort study.

Acta Neurol Scand Suppl 2012 (195):51-7

Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Bergen, Norway.

Objectives: To assess the overall health-related quality of life (HRQoL) in a population-based cohort of patients recently diagnosed with multiple sclerosis (MS) compared with the general Norwegian population, to compare HRQoL among MS patients continuing, switching, stopping or not starting disease-modifying treatment (DMT) and to assess the motivation for DMT according to HRQoL.

Materials And Methods: A multicentre retrospective survey completed by patients recently diagnosed with relapsing-remitting MS (relapsing-remitting multiple sclerosis, RRMS) during 2001-2007 at four university clinics in Norway was performed. HRQoL was measured by the SF-36 version 2 Health Survey and standardized according to the general population with a mean of 50 and a standard deviation of 10. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12033DOI Listing
September 2013

A questionnaire for multinational case-control studies of environmental risk factors in multiple sclerosis (EnvIMS-Q).

Acta Neurol Scand Suppl 2012 (195):43-50

Department of Public Health and Primary Health Care, University of Bergen, Bergen, Norway.

Objectives: The increasing incidence of multiple sclerosis (MS) worldwide, especially in women, points to the crucial role of environmental and lifestyle risk factors in determining the disease occurrence. An international multicentre case-control study of Environmental Risk Factors In Multiple Sclerosis (EnvIMS) has been launched in Norway, Sweden, Italy, Serbia and Canada, aimed to examine MS environmental risk factors in a large study population and disclose reciprocal interactions. To ensure equivalent methodology in detecting age-related past exposures in individuals with and without MS across the study sites, a new questionnaire (EnvIMS-Q) is presented. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12032DOI Listing
September 2013
5 Reads

Incidence and prevalence of multiple sclerosis in Norway.

Authors:
R Midgard

Acta Neurol Scand Suppl 2012 (195):36-42

Department of Neurology, Molde Hospital, Parkvegen 84, Molde, Norway.

The incidence and prevalence of multiple sclerosis in several Norwegian counties have been assessed in a number of epidemiological studies since the first nationwide study covering the period from 1935 to 1948. Although the observations are not continuous, a large increase in incidence and prevalence is reported in these studies. The most remarkable incline has taken place in western and northern Norway. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12025DOI Listing
September 2013

Harmonization: a methodology for advancing research in multiple sclerosis.

Acta Neurol Scand Suppl 2012 (195):31-5

Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada.

Decreasing research funding is in conflict with the increasing need to conduct large studies to examine rare risk factors and interactions between risk factors. As a result, investigators are searching for strategies to stretch research funds and to design studies that will maximize investments already made. Multiple sclerosis (MS) is generally accepted as a multifactorial disease, and the assessment of interactions between risk factors and the desire to assess risk factors within particular sub-groups requires a large number of participants. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12031DOI Listing
September 2013

The Norwegian Multiple Sclerosis Registry and Biobank.

Acta Neurol Scand Suppl 2012 (195):20-3

Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway.

Unlabelled: OBJEVTIVES: Multiple sclerosis is a chronic inflammatory disease of the central nervous system with unknown cause and without any curable treatment. Research aiming at defining the pathogenesis of the disease is therefore needed.

Methods: The Norwegian Multiple Sclerosis Registry and Biobank has been established for systematic collection of clinical and epidemiological data as well as biological samples. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12030DOI Listing
September 2013
1 Read

From the Gothenburg cohort to the Swedish multiple sclerosis registry.

Authors:
O Andersen

Acta Neurol Scand Suppl 2012 (195):13-9

Institution of Neuroscience and Physiology, University of Gothenburg, Sahlgrenska University Hospital, Gröna Stråket 11, Göteborg, Sweden.

An overview of prevalence and incidence studies performed in Swedish centres is provided, showing improving coverage and methodology, notably the development in Gothenburg of the representative incidence cohort design. A common database for major Swedish centres was established in 1995, implementing the terminology of predictors from the Gothenburg cohort. By 2001, these databases were merged into the web-based national multiple sclerosis (MS) registry, which has had an ever-increasing coverage, although with still moderate data density. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12023DOI Listing
September 2013

The use of epidemiological multiple sclerosis registers in research: the Danish MS Registry.

Acta Neurol Scand Suppl 2012 (195):7-12

The Danish Multiple Sclerosis Registry, Rigshospitalet 7801, Blegdamsvej 9, Copenhagen, Denmark.

Introduction: The claim of detection of several environmental risk factors for multiple sclerosis (MS), some of them new, makes the research of population-based MS registers for critical review or confirmation of alleged associations more relevant than ever before.

Aims: To present examples of the use and important contributions from the Danish MS Registry (DMSR) over decades.

Methods: The DMSR has through more than six decades registered virtually all patients with MS in Denmark, using multiple sources of notification and has been used for descriptive epidemiology, follow-up studies, studies of comorbidity and 'historical prospective' studies of proposed risk factors for MS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12022DOI Listing
September 2013

The origin of registry-based medical research and care.

Authors:
L M Irgens

Acta Neurol Scand Suppl 2012 (195):4-6

Locus of Registry Based Epidemiology, Department of Public Health and Primary Health Care, University of Bergen, Kalfarveien 31,Bergen, Norway.

During the last decades, registers comprising medical data have played an increasingly important role in medicine, both in health care and research. It is reasonable to expect that their importance will also increase in the future. Thus, a search for the origin of register-based medicine seems meaningful. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12021DOI Listing
September 2013

A need for national registries and international collaborative research in multiple sclerosis.

Acta Neurol Scand Suppl 2012 (195):1-3

Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway.

Objective: There is a growing need to identify biomarkers for early diagnosis and treatment in multiple sclerosis (MS). Such markers may also be involved in the cause and pathogenesis of the disease.

Methods: Established national MS registries have through several decades allowed data collection to facilitate MS research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12039DOI Listing
September 2013

A vascular approach to mild amnestic cognitive impairment: a pilot study.

Acta Neurol Scand Suppl 2013 (196):73-6

Department of Neurology, Haukeland University Hospital, Bergen, Norway.

Objective: Mild cognitive impairment (MCI) is a subtle memory disorder not matching criteria for dementia. There is evidence for vascular comorbidity in several types of dementia. We hypothesized that neurovascular workup would detect a high degree of vascular disease in patients with MCI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12054DOI Listing

Very long-term mortality after ischemic stroke: predictors of cardiovascular death.

Authors:
O M Rønning

Acta Neurol Scand Suppl 2013 (196):69-72

Medical Division, Department of Neurology, Akershus University Hospital, Lørenskog, Norway.

Background: The purpose of this article is to find possible predictors associated with long-term mortality and long-term cardiovascular death after stroke.

Methods: A cohort of 550 patients with acute stroke admitted to a single hospital within 24 h of a stroke were recruited consecutively. Patients were followed for 12 years or until death. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12053DOI Listing
May 2013
1 Read

Patient selection for intra-arterial cerebral revascularization in acute ischemic stroke.

Acta Neurol Scand Suppl 2013 (196):65-8

Department of Neurology, Cerebrovascular Centre, Oslo University Hospital, Rikshospitalet, Oslo, Norway.

In acute ischemic stroke, rapid revascularization of the cerebral 'penumbra volume' is the key to better patient outcome. The largest and most proximal cerebral thrombotic artery occlusions can in most cases only be opened by intra-arterial intervention. The use of intra-arterial revascularization is rapidly expanding throughout Europe and North America, despite the risk for serious complications and the fact that the benefit of this treatment has not yet been proven in large, randomized clinical trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12052DOI Listing

Acute ischemic stroke--from symptom recognition to thrombolysis.

Acta Neurol Scand Suppl 2013 (196):57-64

Department of Neurology, Stavanger University Hospital, Stavanger, Norway.

Objectives: The understanding of stroke has changed in the recent years from rehabilitation to an emergency approach. We review existing data from symptom recognition to thrombolysis and identify challenges in the different phases of patient treatment.

Results: Implementation of treatment in dedicated stroke units with a multidisciplinary team exclusively treating stroke patients has led to significant reduction of stroke morbidity and mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12051DOI Listing

Visual impairment in stroke patients--a review.

Acta Neurol Scand Suppl 2013 (196):52-6

Section for Neurology, Institute for Clinical Medicine, University of Bergen, Bergen, Norway.

Approximately 30% of all stroke patients suffer from post-stroke visual impairment. Hemianopia is the most common symptom, but also neglect, diplopia, reduced visual acuity, ptosis, anisocoria, and nystagmus are frequent. Partial or complete recovery of visual disorders can occur, but many patients suffer permanent disability. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ane.12050
Publisher Site
http://dx.doi.org/10.1111/ane.12050DOI Listing
May 2013
1 Read

Chronic inflammatory demyelinating polyneuropathy (CIDP).

Acta Neurol Scand Suppl 2013 (196):48-51

Department of Neurology, Haukeland University Hospital, Bergen, Norway.

Background: Chronic immune-mediated demyelinating polyneuropathies can often lead to severe neurologic disability.

Materials And Methods: Literature review and personal experience with these types of neuropathies.

Conclusions: It is important to recognize these immune-mediated neuropathies as they respond to treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12049DOI Listing
May 2013
2 Reads

Chronic Lyme; diagnostic and therapeutic challenges.

Acta Neurol Scand Suppl 2013 (196):38-47

Department of Neurology, Sørlandet Hospital, Kristiansand, Norway.

In this review, we aim to discuss the definition, clinical and laboratory features, diagnostics, and management of chronic Lyme. Chronic Lyme is a rare condition caused by long-lasting and ongoing infection with the spirochete Borrelia burgdorferi (Bb). The most common manifestations are progressive encephalitis, myelitis, acrodermatitis chronica atrophicans with or without neuropathy, and arthritis. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ane.12048
Publisher Site
http://dx.doi.org/10.1111/ane.12048DOI Listing
May 2013
5 Reads

Pseudoprogression in high-grade glioma.

Acta Neurol Scand Suppl 2013 (196):31-7

Department of Neurology, Haukeland University Hospital, Bergen, Norway.

Pseudoprogression is a treatment-related effect seen on imaging in high-grade glioma. Enhancement of gadolinium contrast on control MRI can be misinterpreted as tumor recurrence and is also difficult to distinguish from radiation necrosis. Pseudoprogression is seen in up to 30% after standard treatment for glioblastoma multiforme (GBM), which is radiotherapy concurrent with chemotherapy with temozolomide (TMZ) and adjuvant cycles of TMZ. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12047DOI Listing
May 2013
4 Reads

Clinical assessment and management of sleep disorders in multiple sclerosis: a literature review.

Acta Neurol Scand Suppl 2013 (196):24-30

Department of Neurology, The Norwegian Multiple Sclerosis Competence Centre, Haukeland University Hospital, Bergen, Norway.

The major sleep disorders are common in multiple sclerosis (MS) and are associated with significant morbidity. Despite this, the rate of recognition and management of these conditions are low. All types of sleep disorders are seen in patients with MS: insomnia, circadian rhythm sleep disorders, sleep-related movement disorders, sleep-related breathing disorders, hypersomnia (narcolepsy), and parasomnia (REM sleep behavior disorder; RBD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12046DOI Listing
May 2013
3 Reads

Fat-soluble vitamins as disease modulators in multiple sclerosis.

Acta Neurol Scand Suppl 2013 (196):16-23

Department of Neurology, Norwegian Multiple Sclerosis Competence Centre, Haukeland University Hospital, Bergen, Norway.

Background: Fat-soluble vitamins (A, D, E and K) have properties that could be relevant as modulators of disease activity in multiple sclerosis (MS).

Methods: We performed a systematic search on PubMed and Medline up to May 2012, using the search strings 'vitamin A', 'retinol', 'retinal', 'carotenoids', 'vitamin D', 'vitamin E', 'alpha-tocopherol', 'vitamin K' in conjunction with 'multiple sclerosis', 'animal model' and 'experimental autoimmune encephalitis (EAE)'. In addition, the reference lists of the publications identified were examined for further citations of relevance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12045DOI Listing

Reduced immunoglobulin levels in epilepsy patients treated with levetiracetam, lamotrigine, or carbamazepine.

Acta Neurol Scand Suppl 2013 (196):11-5

Department of Neurology, Oslo University Hospital - Rikshospitalet, Oslo, Norway.

Objectives: The aim of the study was to investigate immunoglobulin levels in patients with epilepsy using the antiepileptic drugs (AED) levetiracetam (LEV), carbamazepine (CBZ), or lamotrigine (LTG).

Methods: A total of 211 patients and 80 controls (age: 18-45 years) of both genders were included. The patients had been treated with either LEV (n = 47), CBZ (n = 90), or LTG (n = 74) monotherapy for at least 6 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12044DOI Listing

Common imitators of epilepsy.

Authors:
E Brodtkorb

Acta Neurol Scand Suppl 2013 (196):5-10

Department of Neuroscience, Norwegian University of Science and Technology, NTNU, Trondheim, Norway.

Many episodic phenomena involving motor, sensory, autonomic, and behavioral functions may imitate epilepsy. The aim of this article is to focus on the various manifestations and the diagnostic and therapeutic challenges of the most common of these disorders, as well as their relationship to emotional aspects. Syncope is caused by reduced global cerebral perfusion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12043DOI Listing
May 2013
3 Reads

The Norwegian Brain Council ('Hjernerådet')--united efforts are necessary!

Acta Neurol Scand Suppl 2013 (196):1-4

Department of Neurology, Oslo University Hospital- Rikshospitalet, Oslo, Norway.

There is a strong tradition of neuroscience in Norway, and Norwegian neurologists have been actively involved in developing partnerships between all those who recognize the importance of the brain and of brain diseases. It was therefore unsurprising that Norwegian neurologists took the initiative in establishing the Norwegian Brain Council (NBC). NBC was founded in 2007 and now comprises 27 organizations and institutions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12042DOI Listing

Zonisamide in clinical practice.

Authors:
S Dupont H Stefan

Acta Neurol Scand Suppl 2012 (194):29-35

Unité d’Epilepsie, Clinique Neurologique Paul Castaigne, Hôpital de la Salpêtrière, 47 Boulevard de l’Hôpital, Paris Cedex 13, France.

Zonisamide is currently licensed in Europe and the USA for the adjunctive treatment of partial seizures (with or without secondary generalization) in adults, based on the results of four pivotal, randomized, double-blind, placebo-controlled trials. It is also licensed in Europe as monotherapy for adults with newly diagnosed partial epilepsy, based on the results of a randomized, double-blind, non-inferiority trial. Because clinical trials are conducted under tightly controlled conditions, using rigid dosing schedules and employing strict exclusion/exclusion criteria, there is a need for 'real-world' evidence of an antiepileptic drug's effectiveness and tolerability in clinical practice, where patients are much more diverse in terms of clinical characteristics and treatment is tailored to the individual's specific needs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12017DOI Listing

Zonisamide: its pharmacology, efficacy and safety in clinical trials.

Acta Neurol Scand Suppl 2012 (194):19-28

Epilepsy Unit, Western Infirmary, Dumbarton Rd., Glasgow, Scotland.

Zonisamide is a benzisoxazole derivative, chemically unrelated to other antiepileptic drugs, that appears to have multiple mechanisms of action, including inhibition of Na(+) channels and reduction of T-type Ca(2+) currents. It is currently licensed in Europe and the USA for adjunctive treatment of partial seizures in adults, and in Europe as monotherapy for treatment of partial seizures in adults with newly diagnosed epilepsy. Zonisamide displays predictable, dose-dependent pharmacokinetics and has a half-life of ~60 h, allowing once- or twice-daily administration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12016DOI Listing
April 2013
1 Read

Ideal characteristics of an antiepileptic drug: how do these impact treatment decisions for individual patients?

Authors:
E Trinka

Acta Neurol Scand Suppl 2012 (194):10-8

Department of Neurology, Paracelsus Medical University, Christian Doppler Klinik, Ignaz Harrer Strasse 79, Salzburg, Austria.

Effective management of epilepsy requires a holistic approach that takes into account the needs of the individual patient. Antiepileptic drug (AED) treatment must therefore look beyond efficacy to ensure that the patient's overall health status and quality of life (QoL) are optimized. Because the primary objective of AED treatment is to control seizures over the long term, the ideal AED should, first and foremost, demonstrate sustained efficacy and favourable tolerability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12015DOI Listing

The impact of epilepsy on patients' lives.

Authors:
M P Kerr

Acta Neurol Scand Suppl 2012 (194):1-9

Welsh Centre for Learning Disabilities, Cardiff University, Cardiff, Wales, UK.

The impact of epilepsy is multifaceted and extensive on its effects. The occurrence of seizures is unpredictable and often dangerous, increasing the risk of injury, hospitalization and mortality, and adversely affecting a patient's mental health, often resulting in anxiety, depression or cognitive impairment. Seizures can also result in stigmatization and social exclusion, with detrimental effects on an individual's confidence and self-esteem. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ane.12014DOI Listing